CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

NCT03068416 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

B-cell Leukemia
B-Cell Lymphoma

Interventions

BIOLOGICAL: CAR T cells

Sponsor

Uppsala University

Collaborators

[object Object]
[object Object]